Genetic and biochemical screening for endocrine disease: II. Ethical issues

被引:4
作者
Kinder, BK
机构
[1] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA
[2] Vet Adm, Connecticut Healthcare Syst, W Haven, CT 06516 USA
关键词
Genetic Testing; Life Insurance; Genetic Discrimination; Biomedical Ethic; Hippocratic Oath;
D O I
10.1007/s002689900546
中图分类号
R61 [外科手术学];
学科分类号
摘要
The ability to test for specific genes conferring susceptibility to a variety of diseases has profound ethical implications for the way in which we care for patients. Legislators and health care insurers are scrambling to address the aspects of genetic screening that they believe fall within their purview. Critical to the development of appropriate societal regulations regarding genetic screening is a fundamental understanding of the ethical issues involved. A review of those concerns and the areas in which they interface with legal and insurance issues is the topic of this paper.
引用
收藏
页码:1208 / 1211
页数:4
相关论文
共 18 条
[1]   The politics of the health insurance portability and Accountability Act [J].
Atchinson, BK ;
Fox, DM .
HEALTH AFFAIRS, 1997, 16 (03) :146-150
[2]  
BEAUCHAMP T, 1994, PRINCIPLES BIOMEDICA, P418
[3]  
BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P351
[4]  
BEAUCHAMP TL, 1994, PRINCIPLES BIOMECIAL, P427
[5]  
BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P145
[6]  
Beauchamp TL, 1994, PRINCIPLES BIOMEDICA, p[67, 120, 194, 256]
[7]  
Beauchamp Tom L., 1994, P3
[8]  
Beauchamp Tom L., 1994, PRINCIPLES BIOMEDICA, V189, P226
[9]  
Croyle RT, 1997, CANCER, V80, P569, DOI 10.1002/(SICI)1097-0142(19970801)80:3+<569::AID-CNCR6>3.0.CO
[10]  
2-4